NEW YORK (Reuters Health) - T cells are the main effector cells in DNA vaccine induced immunity against HER-2/neu (HER-2) expressing tumors. Thus, anti-HER-2 antibodies are not needed to prompt tumor rejection, researchers report in the March 20th issue of the International Journal of Cancer.
Dr. Rolf Kiessling of the Karolinska Hospital, Stockholm, and colleagues note that HER-2 is an oncogene implicated in a variety of cancers.
Anti-HER-2 antibodies have shown some success in treatment of breast tumors. Nevertheless, the researchers point out that the contribution of B cells and antibodies relative to that of T cells in tumor rejection in HER-2 vaccination models “remains unclear.”
To investigate further, the team studied mice immunized using plasmid HER-2 and GM-CSF. Among findings were that protection was associated with the production of anti-HER-2 IgG antibodies in B cell competent mice.
However, when the same procedure was used in B cell-deficient mice, these animals “rejected HER-2 expressing tumors as efficiently as control littermates.” Tumor protection was afforded in the absence of antibodies.
“These results,” the researchers conclude, “therefore argue that tumor-reactive antibodies, induced by vaccination or by a significant tumor burden, may not be needed for tumor rejection and thus are dispensable.”
GM-CSF co-administration was needed to afford “strong protection” in both groups of mice, the investigators add.
They conclude that further efforts should be made “toward developing T cell dependent tumor vaccination strategies based on HER-2.”
Source: Int J Cancer 2004;109:259-264. [ Google search on this article ]
MeSH Headings:Animal Diseases: Animals, Laboratory: Animals, Transgenic: Disease Models, Animal: Immunologic and Biological Factors: Immunologic Factors: Invertebrates: Membrane Proteins: Mice, Transgenic: Receptors, Antigen: Receptors, Antigen, B-Cell: Receptors, Cell Surface: Receptors, Immunologic: Recombinant Proteins: Vaccines, Synthetic: CD4-Positive T-Lymphocytes: Genes, erbB-2: Genes, erbB: Cancer Vaccines: Chemical Actions and Uses: Chemical Actions: Organisms, Transgenic: Chemicals and Drugs: DiseasesCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
